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ABSTRACT
Several reports describe U-shaped 25-hydroxyvitamin D [25(OH)D] concentration–health outcomes,
including musculo-skeletal disorders such as falls and fractures, several cancers, cardiovascular disease
(CVD), cognitive function, all-cause mortality rates, birth outcomes, allergic reactions, frailty, and some
other disorders. This paper reviews reports of U-shaped outcome associations with vitamin D status for
evidence of underlying pathophysiological processes, or of confounding, ﬁnding that some U-shaped
associations appear to be biologically meaningful, but that many could well reﬂect confounding by
factors such as lifestyle, or hypovitaminosis D-related disease onset being masked by self-
supplementation that was begun too late to correct developing health problems but before baseline
vitamin D status assessment. However, the various U-shaped associations for allergic reactions may be
due to vitamin D modulation of the phenotype of the immune response, shifting the Th1-Th2 balance
toward Th2 formation. For prostate cancer, there seems to be little effect of 25(OH)D concentration on
incidence; however, there is an inverse correlation between 25(OH)D concentration and mortality rates.
Future observational studies, and randomized controlled trial data analyses, should include adjustment
for data collected on prior long-term vitamin D supplementation and solar UVB exposure, as well as other
potential confounders.
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Introduction
The study of the health beneﬁts of vitamin D has
expanded in scope during the past 15 y to encompass
many conditions and diseases to include musculo-
skeletal disorders,1,2 chronic disorders such as meta-
bolic syndrome, types 1 and 2 diabetes3 and cardiovas-
cular disease (CVD),4 various cancers,5,6 allergic
reactions,7 neuro-psychiatric disorders, including Alz-
heimer disease8 and autism,9 autoimmune disease,10
pregnancy and birth outcomes,11 respiratory, includ-
ing tuberculosis,12 and other infections, including den-
tal caries.13 Most observational studies have reported
inverse correlations of serum 25-hydroxyvitamin D
[25(OH)D] with health outcomes. However, a few
studies also reported adverse outcomes with higher 25
(OH)D concentrations, suggesting caution is needed
in considering vitamin D supplementation >10,000
IU/d (>250 mg/d) until this phenomenon is under-
stood,14 and existing clinical trials have been examined
for the safety of higher vitamin D3 doses.
15
Methods
In an attempt to resolve those discrepancies we reviewed
the literature on vitamin D and health outcomes to deter-
mine how to consider upturns in adverse outcomes with
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higher vitamin D status. Using the National Library of
Medicine’s PubMed database and Google Scholar, we
focused on health outcomes for which studies found U,
or similarly shaped, associations between 25(OH)D con-
centration and health outcomes.We also searched related
articles and links and, by manually searching references
cited in key reports, identiﬁed some additional articles.
We evaluated the magnitude and relevance of the evi-
dence for U-, or similarly shaped, associations. In each
case, we considered whether explanations can be offered,
either to account for the observed relationship, or to sug-
gest that the observed relationships were not necessarily
causal, but could be explained by covariates not normally
considered in studies on vitamin D status and health
outcomes.
Results
Cancer
Only a few studies report either a direct (positive) or a
U-shaped relation between serum 25(OH)D concen-
trations and later cancer incidence. This section
reviews these studies, pointing out strengths and
weaknesses.
Pancreatic cancer
Two prospective observational studies reported
increased risk of pancreatic cancer incidence with higher
25(OH)D concentrations: one in Finland16 and one in
the United States.17 However, when the US cohort was
examined by regions of low and high residential sun
exposure, people with low sun exposure had a signiﬁ-
cantly higher incidence rate, with baseline 25(OH)D
concentrations of>78 nmol/L and<49 nmol/L, respec-
tively, while those living in regions with high sun expo-
sure had insigniﬁcantly increased risk: the authors noted
that 25(OH)D concentrations were a total of vitamin D2
and D3 metabolites. In comparison, 2 prospective
observational studies of participants enrolled from the
entire United States (one based on “predicted vitamin D
levels;”18 the other, a pooled analysis of 5 nested case–
control studies),19 found inverse correlations between 25
(OH)D concentrations and pancreatic cancer risk. One
feasible explanation for the discrepancy between these 2
studies, is that people living in regions of low sun expo-
sure were taking vitamin D supplements, possibly begun
shortly before enrollment and blood sampling. A recent
paper reported that 25(OH)D2 was detected in 57% of
blood samples that had a total 25(OH)D >125 nmol/L
in blood samples collected from adults in the United
States throughout the year. Since vitamin D2 is the main
form of vitamin D that is available in United States on
prescription, these data suggested that a majority of
patients were being treated with vitamin D, and proba-
bly for deﬁciency.20 Geographical ecological studies sup-
port a role of solar ultraviolet-B (UVB) radiation in
reducing risk of pancreatic cancer through vitamin D
production and possibly other mechanisms.6
Prostate cancer
Observational studies associate both the lowest and
highest 25(OH)D concentrations with increased risk of
prostate cancer (PC). The ﬁrst study from Scandina-
vian countries reported a U-shape association of 25
(OH)D with PC risk in 2004.21 The ﬁndings for this
and similar studies reporting U-shaped 25(OH)D con-
centration-PC incidence relations are given in Table 1.
The 25(OH)D concentration associated with mini-
mum risk of PC incidence in these studies varies from
<16.3 nmol/L to 72.9 nmol/L. One possible problem
with these studies is that long follow-up times were
used. However, in an analysis of the effect of follow-up
time on 25(OH)D concentration and cancer incidence
associations for colorectal cancer, after up to 14 years,
still showed signiﬁcant inverse correlations for risk
with both high and low 25(OH)D concentration, while
Table 1. Reports of U-shaped 25(OH)D concentration-PC incidence relations.
Location
Follow-up
period (yrs)
Optimal 25(OH)D
concentration (nmol/L)
Adverse higher 25(OH)D
concentration (nmol/L) Reference
Finland, Norway
and Sweden
Up to 11, 16, or 24,
depending on country
40–59 80 21
Finland Up to 20 <16.3 23.8–33.3 and >45 23
Sweden Up to 14 <68 85–102 24
Norway Up to 25 30–69 >69 25
USA Up to 8 58.2–72.9 >72.9 26
France 13 >62 Not given 27
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for breast cancer, signiﬁcant inverse correlations were
found only for follow-up times less than 3 y.22 For PC,
the results were generally not signiﬁcant for follow-up
times between 4 and 28 y.
A recent meta-analysis of 21 observational studies
found an odds ratio (OR) for PC, for highest versus
lowest 25(OH)D quartiles, of 1.17 (95% conﬁdence
interval [CI], 1.08–1.27).28 Twelve of the studies were
from the US.
One possible confounding factor that might help
explain the slight increased detection of PC for those
with higher 25(OH)D concentrations is the wide-
spread use of the PSA test for screening. By the early
1980s, PC incidence rates in the US started to climb,
peaking at a 120% increase by 1992 before declining
to a 50% increase through the early 2000s.29 At the
same time, mortality rates rose by 30% by 1992 before
declining to pre-PSA era rates by 2002. PSA screening
has been widespread, but with different effects on
mortality rates in different countries.30 It could be the
case that men who are more health conscious have
both higher 25(OH)D concentrations and are more
likely to use PSA screening for PC detection.
There is, however, good evidence that higher 25(OH)
D concentrations are associated with reduced risk of
lethal PC. A prospective nested case-control study from
the Health Professionals Follow-up Study involving
1260 men who were diagnosed with PC between 1993
and 2004 found that those in the highest 2 25(OH)D
quartiles had signiﬁcantly lower risk of fatal PC com-
pared to those in the lowest quartile; however, there
were no signiﬁcant differences in risk of PC with respect
to 25(OH)D concentration.31 Analysis of deaths for
1000 PC cases from the Alpha-Tocopherol, Beta-Caro-
tene Prevention Study in the US found that for those
who survived >3.3 years, the hazard ratio for death for
high vs. low quintile of 25(OH)D concentration from
time of enrollment was 0.53 (95% CI, 0.34–0.85, PtrendD
0.0002).32 The effect for shorter times was insigniﬁcant.
In a clinical trial in which 48 men with low-grade
PC and mean baseline 25(OH)D concentration of
82 nmol/L took 4000 IU/day vitamin D3 for a year,
33
they reached a mean 25(OH)D concentration of
166 nmol/L. PC progression in comparisons of repeat
biopsy outcome was observed in 34% of the partici-
pants compared to 63% of historical controls while
55% had improvement on repeat biopsy compared
with 21% of historical controls,33 suggesting that
vitamin D may reduce progression of PC.
PC grade may play an important role in explaining
the possible U-shaped pattern. Analysis of serum 25
(OH)D with advanced vs. localized PC, and by Glea-
son grade (high vs. low) demonstrated an increased
risk of more aggressive PC in men with 25(OH)D con-
centrations <30 nmol/L.34,35 Two single-nucleotide
polymorphisms (rs4588-A and rs7041-T) in the gene
for vitamin D–binding protein, associated with low 25
(OH)D concentration, are also associated with
increases in both PC risk and grade.36 However,
higher serum 25(OH)D concentrations may modestly
increase PC risks at Gleason scores of 2–6 but reduce
the risks of more aggressive PC at Gleason 8–10.26,37
Confounding of incidence rates of disorders in rela-
tion to risk factors that affect survival, independent of
the disorder itself, is well recognized (Neyman’s sur-
vival bias38). However, increasing age is recognized to
be associated with lower values of serum 25(OH)D;
thus, the association of increased PC rates with higher
serum 25(OH)D values, producing U-shaped associa-
tions, is unlikely to reﬂect the Neyman effect, a view
supported by the age-matched (within 6 months at
enrolment) data for 652 cases and 752 controls that
shows no signiﬁcant correlation of PC incidence with
respect to 25(OH)D concentration.39
All-cancer mortality rate
The Uppsala Longitudinal Study of Adult Men used
blood samples from 1991–1995 and monitored partic-
ipants through 2007.40 It found higher cancer inci-
dence and mortality rates for the top 95th percentile
of 25(OH)D concentrations for cancer, but not for
CVD. The mean age of the men at baseline blood
draw was 71 y in 1991–1995, and the lower end of the
95th percentile was 100 nmol/L (40 ng/ml). The
authors suggested several mechanisms whereby higher
25(OH)D concentrations could be associated with
cancer risk, including well-known effects such as stim-
ulation of the vitamin D catabolic enzyme,
(CYP24A1), increased production of insulin-like
growth factor; and suppression of the farnesoid X
receptor that detoxiﬁes carcinogenic bile acids, reduc-
ing risk of cancer of the enterohepatic system. The fol-
low-up period for the Uppsala study was about 14 y.
In a study in Norway, the correlation coefﬁcient for 25
(OH) D concentrations at baseline and 14 y follow up
was between 0.39 and 0.52,41 a factor likely to affect
the strength of long-term prospective associations.42
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Cardiovascular disease
Two of 24 prospective studies of this association iden-
tiﬁed in 20124 found U-shaped relationships between
25(OH)D concentration and CVD events, or deaths
[in Israel43 and in Denmark44]; their ﬁndings are
shown in Table 2, but present obvious anomalies. The
Israeli study did not distinguish acute coronary events
from all-cause deaths - the authors noting that only
29% of deaths in the study group (aged >45 y old),
were due to CVD., while the German study dealt with
a small population subgroup, subjects undergoing car-
diac surgery. Furthermore, those with the highest 25
(OH) D concentrations were very small fractions of
the study groups (1.5%–5.0%).
In contrast to those ﬁndings, a meta-analysis of CVD
incidence or mortality rate, based on 19 independent
studies with 6,123 CVD events, including deaths, in
65,994 participants, found a relative risk (RR) of 1.0 for
25(OH) D concentrations >75 nmol/L, although there
were only 2 data points for higher concentrations, (93 or
110 nmol/L).4 A more recent meta-analysis considered
values >90 nmol/L, the highest 25(OH)D concentration
decile, and found noU-shaped relationship.46
Despite the confusion in the ﬁndings for U-shaped
relationships of outcomes with vitamin D status, the pos-
sible confounding factors, explaining such associations,
are of interest. Zittermann found that those with the
highest 25(OH)D concentration had low 1,25-dihydrox-
yvitamin D concentrations, and hypothesized that
reduced activation of 25(OH)Dmight account for the U-
shaped associations in some disorders.47,48 Another feasi-
ble explanation is that subjects started taking vitamin D
after disease development, but before vitamin D status
assessment, in various types of association studies. This
factor is increasingly likely, with the increasing media
coverage on the need to take more vitamin D, as a result
of sun avoidance for avoidance of skin cancers. Two
cross-sectional studies of frailty status in the elderly with
respect to 25(OH) D concentrations in the United States
provide some support for this view; in men, an inverse
linear relationship49 was found, but in women, a U-
shaped relationship was found,50 and it is common prac-
tice to supplement older women, but not men, with vita-
min D in the USA, as inmanyWestern populations.
Thus, though some evidence exists for a U-shaped
CVD risk relationship with vitamin D status, it could
be due to confounding by taking vitamin D supple-
ments pre-study, but too late to have prevented dis-
ease development, or due to D2 supplementation
which may or may not have effects on CVD risks.
Clariﬁcation on whether or not increases in serum
25(OH)D can have adverse effects on the cardiovascu-
lar system if they rise above some speciﬁc concentra-
tion requires further studies that can assess intakes
from diet of D3, D2, and their 25-(OH)D metabolites,
as well as of other nutrients known to affect the CVS
(including calcium, magnesium, lipids), and also levels
of supplementation and when it began.
Falls, fractures, and frailty
As well as having established beneﬁts on calcium
metabolism and musculoskeletal health, several lines
of evidence link adequate vitamin D status to muscle
strength and lower risks of falls.51 Proximal muscle
weakness is a feature of clinical vitamin D deﬁciency;
52vitamin D receptor (VDR) is expressed in human
muscle53-56 and vitamin D activation promotes de
novo protein synthesis, preferentially, in type II fast
twitch muscle ﬁbers, (relevant in fall prevention.51,53,56
Though several meta-analyses of clinical trials of vita-
min D supplementation suggest reductions in falls57-60
and fractures,61-63 these outcomes have varied with
variations in trial design, and trials selected for
meta-analysis.57,62,64 Furthermore, these outcomes
may also vary with vitamin D dosage, dosing interval,
and achieved 25(OH)D concentrations. For example,
2 meta-analyses show daily low-dose vitamin D was
ineffective when compared with daily doses of 800 IU/
Table 2. Results of the 2 observational studies with U-shaped 25(OH)D concentration-CVD risk associations.
Study Location Outcome examined Type of Study 25(OH)D (nmol/L) Fraction of Cases HR (95% CIs) Reference
Israel MACS Historical prospective >90–100 0.05? HR D 1.08 (1.00–1.11) 43
MACS Historical prospective >100 0.03 HR D 1.13 (1.01–1.21) 43
Germany MACCE Prospective >100 0.03 OR D 2.34 (1.12–4.89) 45
Denmark CVD mortality Prospective <75–100 0.12 MR D 1.10 44
CVD mortality Prospective >100–125 0.04 MR D 1.44 44
CVD mortality Prospective <125 0.02 MR D 1.51 44
95% CI, 95% conﬁdence interval; HR, hazard ratio; MACCE, major adverse cardiac and cerebrovascular events during of cardiac surgery or while still at the hospital;
MACS, mortality or acute coronary syndrome; MR, mortality rate; OR, odds ratio.
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day.57,59,65 Trials of higher doses of vitamin D for fall
prevention are limited, but one showed no fall reduc-
tion in 173 frail seniors post- acute hip fracture with
2000 IU vitamin D/day vs. 800 IU/day over 12 months
(HR 1.28; 95% CI: 96%, 168%),66 with an achieved
mean 25(OH)D concentration at 12 months of
111.5 nmol/L in the 2000 IU/day group vs. 88.5 nmol/
L in the 800 IU/day group. A further trial in 2256
senior women at high risk of hip fracture using an
annual bolus of 500,000 IU of vitamin D vs. placebo,
increased fall rates (RR=1.15; 95% CI:1.02–1.30),67
with an achieved mean 25(OH)D concentration of
120 nmol/L at 1 month and 90 nmol/L at 3 months
post dose, by which time most additional falls had
happened. A more recent trial tested 3 monthly doses
of vitamin D among 200 community-dwelling seniors
who all had fallen in the prior year.68 Of the 200 par-
ticipants, 60.5 percent (121 of 200) fell during the 12-
month treatment period. The two monthly high dose
groups, 60,000 IU and 24,000 IU plus calcifediol, had
no beneﬁt in lower extremity function and had signiﬁ-
cantly higher percentages of participants who fell
(66.9 percent and 66.1 percent, respectively) compared
with the 24,000 IU group (47.9 percent). Participants
in the 24,000 IU vitamin D group (equivalent to 800
IU/day) also experienced the most improved lower
extremity function as well as the fewest number of
falls. A consistent pattern was seen by achieved 25
(OH)D blood concentrations. The best functional
improvement and fewest falls were observed at the
lower replete 25(OH)D range of 53.3 to 75.8 nmol/L,
while no functional beneﬁt, plus most falls, were
observed between 111.8–247.3 nmol/L68. These trials
both suggest that the risks of falls and fractures may
be increased in seniors if achieved serum 25(OH)D
concentrations reach >112 nmol/L, a ﬁnding requir-
ing further investigation. One explanation may be that
there is a therapeutic range for vitamin D with respect
to fall prevention among seniors who had a prior fall.
In fact, the most recent study points to the range
between 53 to 76 nmol/L as optimal because both 25
(OH)D concentrations below 53 nmol/L (vitamin D
deﬁciency) and above 112 nmol/L were associated
with increased risk of falling. An alternative explana-
tion may be that higher bolus doses of vitamin D are
not advantageous. Also, if higher serum 25(OH)D is
associated with a tendency to walk more, which is
likely, an individual may be at higher risk of the type
of trips and falls that occur while walking. Patients
who are bedbound or very sedentary will be less
exposed to walking and to risk of tripping and falling
while walking. So this ﬁnding does not directly impli-
cate vitamin D as an etiological factor.”
For fracture prevention, similar ﬁndings have
emerged,61,69. Two meta-analyses of double-blind
RCTs support minimal daily doses of 800 IU of vita-
min D for fracture prevention at any non-vertebral
site [14%to 20%57] and at the hip [18% to 30%70], vs.
lower doses, and fracture prevention was found in
RCTs that achieved mean 25(OH)D concentrations of
75 to 112 nmol/L.57,71 Higher doses of vitamin D were
explored in 3 large trials for fracture prevention, one
used 100,000 IU vitamin D3
71 given orally, 4 monthly,
one gave 300,000 IU vitamin D2
72 intra-muscularly
4 monthly, and another gave oral boluses, yearly, of
500,000 IU vitamin D3.
67 While the fracture risk was
reduced with treatment in the lowest dose trial, (RR D
0.78 (95% CI 0.61 to 0.99) for any ﬁrst fracture71),
both of the higher annual bolus dose trials increased
fracture risks (RR D 1.09 (95% CI 0.93–1.28); 72 RR D
1.26 (95% CI 1.00–1.59; P D 0.04767 for any ﬁrst frac-
ture), with mean achieved 25(OH)D concentrations of
75 nmol/L in the lowest dose RCT,71 and most
markedly raised with the annual 500,000 IU dose with
mean achieved concentrations of 120 nmol/L.67
Notably, the physiology behind a possible detrimental
effect of a high dose of vitamin D monthly or less fre-
quently on muscle function, falls and fractures, may
well include increased catabolism of activated vitamin
D, but remains unclear and needs further
investigation.
One recent observational study, from Australia,
found a decrease in fracture rates in older men from 36
fractures/323 persons with baseline 25(OH)D concen-
trations<36 nmol/L and 13 fractures/355 persons with
baseline 25(OH)D concentrations of 36 to 73 nmol/L,
and 35 fractures/340 persons with 25(OH)D concen-
trations >73 nmol/L.73 While vitamin D supplement
use was »8% for both men who suffered fractures and
those who did not, these data reﬂect either adverse
effects of higher vitamin D status, or unidentiﬁed con-
founding, possibly by vitamin D supplementation, (or
UVB exposure) being more common in those with the
highest status, or by concomitant vitamin A supple-
mentation, but the report was unable to report supple-
mentation rates in the various subgroups.
Two ongoing trials (VITAL74 and DO-HEALTH
(http://do-health.eu/wordpress/)) test 2000 IU vitamin
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D3/day for fall and fracture reduction, but patient char-
acteristics differ from many others in targeting rela-
tively healthy older adults and seniors, and by
supplementing with additional Omega-3 FFAs in the
VITAL study. These trials should, however, provide
important opportunities to determine whether there is
an optimal range of serum 25(OH)D concentration for
fall and fracture prevention and whether supplementa-
tion reduces these risks or not. Another randomized
placebo-controlled clinical trial using 2,000 IU/day of
vitamin D3 and 1,500 mg/day of calcium in 2,300 par-
ticipants studied for 4 y just ended at Creighton Uni-
versity in Omaha NE. Analysis of the effect of this
intervention on disease incidence has begun, and the
results will be submitted for publication soon.
Frailty
Serum 25(OH)D concentrations and frailty status
were assessed in a cohort of 6307 community-dwelling
women aged 69 years enrolled in the US. Study of
Osteoporotic Fractures, and both lower (<50 nmol/L)
and higher (75 nmol/L) values of 25(OH)D were
moderately, but signiﬁcantly, associated with a higher
risk of baseline frailty.50 In men however, a similar
study found a monotonic inverse relation between 25
(OH)D values and frailty status.49 Thus, while a U-
shaped association cannot be excluded for vitamin D
status and concomitant frailty in women, such an
association was not seen in men; also, since elderly
women are much more likely to be given vitamin D,
especially when frail, confounding by indication (i.e.
placement in the wrong long-term 25(OH)D category)
in the Study of Osteoporotic Fractures, in women,
could explain the U-shaped curve.
Overall, there is no RCT data, to date, to determine
whether there is an optimal vitamin D status for
frailty, or a simple threshold serum 25(OH)D for
reduction in the risks of frailty.
Cognitive function
Vitamin D has emerged as a neurosteroid hormone
involved in brain health and function.75,76 Neuroepi-
demiology has consistently shown positive linear associa-
tions between serum 25(OH)D concentration and
cognitive performance,77-79 and 3 studies have reported
U-shaped relationships, with worse cognitive scores with
both lower and higher 25(OH) D concentrations.80-82
The ﬁrst, using data from NHANES III,80 reported
cognitive differences between 25(OH)D quintiles - par-
ticipants in the highest quintile (25(OH)D >85.4 nmol/
L) being most memory impaired, though this signiﬁcant
ﬁnding (p D0.02) was not clinically meaningful, and, as
no adjustment for multiple comparisons was made, the
authors interpreted this ﬁnding as a false positive.80 The
second paper found a U-shaped association for 45 y olds,
prospectively, between 25(OH)D concentrations and
word recall aged 50 y (pcurvatureD0.01),81 but had more
postmenopausal subjects in both the groups with concen-
trations < 25nmol/L and 100 nmol/L, suggesting that
provision of vitamin D to menopausal women might
have driven the U-shaped ﬁndings. The third paper, on
data from the Newcastle 85C study,82 found participants
in the lowest and highest 25(OH)D quartiles to have
increased risks of cognitive disorders (RR=1.62, pD0.04)
vs. those in the middle quartiles, and at baseline, but not
at 3-year follow-up; this U shaped association was
observed solely in participants using vitamin D supple-
ments, suggesting that it could have been driven by sup-
plementation of those with hypovitaminosis D that had
begun after the onset of cognitive disorders.
Compared with the growing body of evidence for a
positive linear relationship between 25(OH)D and
cognitive ability in adults,78,79,83 with a possible
threshold effect,8,79,83 data in favor of a U-shaped rela-
tionship are scarce,80-82 and might be due to chance,
or to late-onset supplementation, a possibility requir-
ing investigation.
All-cause mortality
A meta-analysis of 32 studies84 revealed no U- or
J-shaped relationship of serum 25(OH)D, [or of ter-
tiles, quartiles or quintiles of serum 25(OH)D] with
all-cause mortality, which was inversely associated
with lower all-cause mortality rates (p < 0.01), with
no evidence of publication bias according to a funnel-
plot analysis (see Figure 3 of that paper) for serum 25
(OH)D values up to »175 nmol/L (70 ng/ml) and
showing no adverse association of these serum 25
(OH)D values with all-cause mortality. These data do
not rule out that extremely high serum 25(OH)D
concentrations [e.g. 400 nmol/L (160 ng/ml)] may be
associated with increased all-cause mortality though
not all studies have been in agreement. This meta-
analysis, with 32 cohort and 2 nested cased-control
studies included several studies in which participants
were patients rather than healthy people. The
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age-adjusted hazard ratio for all-cause mortality
showed a linear decrease up to 90 nmol/L (36 ng/mL),
above which no further change occurred. Another
meta-analysis in 2012 included 14 prospective cohort
studies for generally healthy community-dwelling
individuals, with 5,562 deaths in 62,548 individuals.85
The minimum relative risk was found with values
near 80 nmol/L, with nonsigniﬁcant increases at
concentrations up to 115 nmol/L.
Two papers from Denmark reported reverse-J
shaped associations, one for all-cause mortality and 25
(OH)D concentration,86 and one for CVD mortality,44
though the authors did not claim causality in the
absence of data on vitamin D supplementation.87
A prospective study of all-cause mortality rates in
very old men and women (>85 years) in Newcastle82
offers some support for the suggestion of ’recent vita-
min D supplementation’ since for men, neither low
nor high 25(OH)D concentration was associated with
increased mortality rate. However, for women in the
upper quartile (47 nmol/L in spring and 69 nmol/
L in summer), signiﬁcantly increased hazard ratios for
mortality emerged in all 4 models, but when the analy-
sis was restricted to women not taking vitamin D sup-
plements, the hazard ratio for mortality was not
signiﬁcantly increased.
An American study found that patients admitted to 2
hospitals in Boston had signiﬁcantly higher 90-day mor-
tality rates for 25(OH)D concentrations<75 nmol/L and
>150 nmol/L88 and one clinical trial reports that patients
in intensive care in a hospital in Austria, where the study
group received 540,000 IU of vitamin D3 shortly after
admission and 90,000 IU of vitamin D3 per month there-
after had a nonsigniﬁcantly reduced 6-month mortality
rate, but no indication of increasedmortality.89
Pregnancy
We have found 2 birth outcome studies that have
reported a U-shaped relation of outcomes to 25(OH)
D concentration. One from the Pittsburgh in 1997–
2001, with blood-sampled between the 16th and 22nd
week of pregnancy where white women with 25(OH)
D concentration >75 nmol/L had an odds ratio of 2.1
(95% CI, 1.2–3.8) for having small-for-gestational-age
neonates.90 The authors could not explain their ﬁnd-
ings but did mention confounders such as consump-
tion of oily ﬁsh (which contains pollutants, including
mercury, which reduces birth weight).91 Similar
ﬁndings were reported in a recent study from Hefei,
China, which examined the association of cord blood
concentrations of 25(OH) D in 1491 neonates and
birth weight. Birth weight increased by 61.0 g (95%
CI, 31.9–89.9 g) at concentrations less than 40 nmol/L
and then decreased by 68.5 g (95% CI, ¡110.5 to
¡26.6 g) at concentrations from 40 to 70 nmol/L.92
The 95% CIs at the extremes of low and higher 25
(OH)D concentrations were for birth weights below
their 95% CIs, at 25(OH)D values<40 nmol/L for
both male and female offspring. However, the lack of
data to allow adjustment of the ﬁndings for relevant
factors such as outdoor activity, dietary intake, envi-
ronmental factors, or genetic variation, means that
residual confounding was not excluded.
Allergies
A Finnish birth cohort study suggested a different
relationship between vitamin D status and allergic dis-
eases. Infants (nD5007 out of 7648 studied) were sup-
plemented with vitamin D during the ﬁrst year of
life.93 The prevalence of atopy, allergic rhinitis, and
asthma at age 31 y was higher in people who, as
infants, had been supplemented regularly with
approximately 2000 IU of vitamin D per day—a dose
signiﬁcantly higher than that usually recommended
for infants.94 Those associations (other than for
asthma) remained signiﬁcant after adjustment for
potential confounders, but data for serum 25(OH)D
concentrations were unavailable. Another study,
reported an almost twofold increase in susceptibility
to asthma and food hypersensitivity after supplemen-
tation with vitamin D (400 IU/d) and vitamin A (1000
IU) for the ﬁrst year of life.95 The increase in allergic
disease in that study could not be attributed to vitamin
D supplementation per se, since infants were also sup-
plemented with vitamin A, which appears to be an
independent risk factor for asthma.96 A Swedish birth
cohort study reported similar ﬁndings prospectively
when 123 children were studied, in conjunction with
vitamin D and vitamin A supplemental intake data,
during the ﬁrst 24 months of life.97 A large birth pro-
spective cohort study associated maternal 25(OH)D
concentrations >75 nmol/L during late pregnancy
with increased offspring eczema risks aged 9 months,
and asthma risks aged 9 years;98 however, limitations
of that study included the small number of incident
allergic conditions (nD15 for atopic eczema at
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9 months and nD9 for asthma at 9 years), a high drop-
out rate by age 9 years, and the absence of data on
vitamin D or A supplementation. Randomized, dou-
ble-blind, placebo-controlled trial data from Japanese
children showed that those receiving 1200 IUs of vita-
min D daily for 4 months during the winter, reduced
both their inﬂuenza infection risk by 42%, and their
asthmatic attack rates by >90%.99
A large cross-sectional study of participants in the
fourth decade of life (n D 7288) with serum 25(OH) D
concentrations>135 nmol/L found a signiﬁcant increase
in immunoglobulin E concentrations (29% higher) vs.
the reference group.100 Cord blood 25(OH) D concentra-
tions 100 nmol/L were associated with signiﬁcantly
higher total, and allergy-speciﬁc inhalant immunoglobu-
lin E concentrations in a birth cohort from Arizona,101
and with rates of skin-prick test positivity (adjusted OR,
3.4; 95% CI, 1.0–11.14; pD 0.046), using 25(OH) D con-
centrations at birth, without data on supplementation,
dietary habits, or sunshine exposure.101 However,
another prospective study associating increased risk of
wheezing with higher 25(OH) D concentrations,102
found no association of lower vitamin D status with
upper respiratory disease risks. Similar results were seen
in a cross-sectional study in children aged 6–12 years,
where 25(OH)D concentrations 75 nmol/L were asso-
ciated with increased risk of wheezing (OR, 2.14; 95% CI,
1.07–4.28) vs. children with 25(OH)D concentrations of
50-<75nmol/L.103 Signiﬁcant numbers of that cohort
(46.9%)were in the highest 25(OH)D concentration cate-
gory; however, as the authors report, the study was con-
ducted in the north, (43N latitude), with children
receiving sunlight for short durations, even in the
summer. These authors later associated high 25
(OH)D concentrations with lower mean FEV1/FVC
ratios.104 Mid-pregnancy and dietary lifestyle char-
acteristics and maternal mid-pregnancy 25(OH)D
concentrations 100 nmol/L were associated with
increased risks of child asthma at 18 months (RR
D 1.36). Measurements of offspring 25(OH)D con-
centrations at birth or during childhood were not
available.105 The same group later replicated those
ﬁndings in the same birth cohort,106 and also asso-
ciated in utero exposure to higher maternal 25
(OH)D concentrations (125 nmol/L) with
increased risks of asthma hospitalizations and self-
reported asthma (HR, 1.81; 95% CI, 0.78–4.16 and
OR, 1.82; 95% CI, 0.81–4.04) vs. the reference
group (maternal values, 75–125 nmol/L).
Overall, data indicating associations between vita-
min D status and allergy risks are derived mainly
from studies using single time-point serum concentra-
tions, and not monitoring vitamin D supplementation.
Signiﬁcant variables, such as prior exposure to vitamin
D, C/¡ other supplements and potential confounders,
with clearly deﬁned allergy outcomes, will be essential
in future supplementation studies, as in any search for
evidence of a causal relationship.11
Other diseases
One study reports a U-shaped association between
vitamin D status and hypogonadism in men, suggest-
ing an unexplained optimal 25(OH)D concentration
of 82–102 nmol/L in men.107 Data on vitamin D
intake and use of vitamin D supplements during or
prior to the study were not reported, which may
explain the higher vitamin D concentrations com-
pared with what was previously described in healthy
populations.108 Overall, no conclusions indicating
causality between vitamin D status and hypogonadism
could be drawn because of the cross-sectional design
of available studies.107,109,110
Discussion
There are several health outcomes for which a U, or
similarly shaped, relationship with serum 25(OH)D
concentrations has been suggested, most consistently
for allergic reactions, PC, and cardiovascular disease.
(Table 3).
There are several possible explanations for apparent
or artifactual U-shape curvilinear relationships
between serum 25(OH) D and health outcomes. Some
are speciﬁc, depending on problem and the mecha-
nisms affecting the health outcome; others are more
general, or linked to vitamin D supplementation in
response to early signs or symptoms of a disease. For
instance, allergic worsening at high 25(OH)D concen-
tration could be explained by vitamin D’s role in
shifting the Th1–Th2 balance in favor of pro-inﬂam-
matory factor secreting Th2 cells; 112 the occasional
purported U-shaped 25(OH)D concentration–CVD
mortality association may reﬂect lower 1,25(OH)2D
formation due to concomitant kidney dysfunc-
tion113,114 or to enhanced calcitriol catabolism, or to
various biases that can inﬂuence results.
Some U-shaped relationships, seen sporadically, may
be due to chance, or explained by unidentiﬁed
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confounding factors. One important confounding factor
that may affect studies reporting adverse health outcomes
at higher 25(OH)D concentrations is supplementation
with vitamin D that starts too late to affect disease pro-
gression, but before blood draw for 25(OH)D measure-
ment. For overall mortality rate, for example, some
U-shaped ﬁndings may be related to late onset supple-
mentation, or treatment of long standing deﬁciency, since
with the current heightened awareness of the health ben-
eﬁts of vitaminD,many physicians are now recommend-
ing supplementation, especially for elderly subjects at risk
of osteoporosis. In addition, many people now self-
administer vitamin D supplements in response to
increased media coverage on sunshine avoidance, on the
lack of sunshine, and on the more widely recognized
need to take vitamin D supplements. Further support for
vitamin D supplementation accounting for associations
of apparent adverse effects with 25(OH)D concentration
was found in the >3.8 million values from the United
States (January 2007-December 2009), where 2678 (57%)
of participants with 25(OH)D concentrations
>125 nmol/L had 25(OH)D2 values>10 nmol/L,
20 again
suggesting they were taking vitamin D2 supplements.
Another concern about observational studies of
health associations with serum 25(OH)D concentra-
tions is that the assays themselves have analytical
biases. Comparing values measured in 3 laboratories
with values from a Vitamin D External Quality Assess-
ment (DEQAS) compliant laboratory showed liquid
chromatography-tandemmass spectrometrymean val-
ues from 2 centers were higher than certiﬁed laboratory
results by 16.5 and 16.9 nmol/L, and these increases
were greatest at higher values, but means from the cen-
ter using DiaSorin Liaison were 11.1 nmol/L different
from DEQAS ﬁndings.115 This problem has been noted
to affect the setting of dietary guidelines.116 DEQAS,
Table 3. Summary of ﬁndings.
Outcome
of interest
Studies
(N) with ‘U’-
shaped ﬁndings, by topic
Type
of study Reference Validity Comments
Possible Non-causal
confounders Identiﬁed
Allergies Probable Common ﬁndings Shift of Th cell balance
from Th1 to Th2
cells, increasing
inﬂammatory
cytokines
Cancer, of the
prostate
6 NCCMeta-analysis 21,23,24,26,28 Probably not Confounding by PSA
testing possible
Unknown
Pancreatic Cancer 2 NCC 16,17 No Not found at lower
latitudes
Possible recent high-
dose vitamin D
supplementation
(before blood draw)
CVD 3 Prospective 43-45,111 Probably not U-shaped relationship
found in 3studies; 1,25
(OH)2D measured in
one study. Not found
in most studies.
Recent vitamin D
supplementation,
meat consumption,
low 1,25(OH)2D
production
Cognition 3 80-82 No Weak studies, not
consistent in
outcomes
Recent vitamin D
supplementation
Falls, fractures, bolus
doses
2 67,72 Maybe Repeated
Fractures 1 Prospective 73 No Recent vitamin D
supplementation
Frailty status 1 Cross-sectional 50 No Observed for women but
not men
Recent vitamin D
supplementation
Mortality rate 3 40,86,88 Probably not Observed in some studies;
found for some
outcomes
CVD, PC.
Pregnancy outcomes 2 90,92 No Found in only 2 studies Not known, but 25(OH)
D was measured at
<22 weeks’
gestation or at term
at a single time point
Data on dietary
intake (vitamins A, C,
K; calcium; and
magnesium) not
available
NCC, nested case–control
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established to help laboratories ensure the accuracy of
their measurements,117 can 117(117)[117](117)(115)
(118)be used to standardize (harmonise) historical val-
ues,118 a measure that can be expected to reduce the
ﬁnding of U-shaped 25(OH)D concentration-health
outcome relationships, since fewer high 25(OH)D con-
centration values would probably be found; however,
though assay standardization would reduce bias as a
confounder, whether it would abolish the markedly U-
shaped ﬁndings reported for some diseases is
unknown, and needs to be investigated.
The lack of data allowing assessment of the impor-
tance of nutritional confounding factors is concerning,
and researchers conducting future observational studies
and randomized controlled trials should obtain vitamin
D supplementation histories from participants, and data
for when supplementation began, so that analyses can
allow for different durations of supplementation before
outcome analysis. Furthermore, where early life intakes
appear able to affect risk factors before disease becomes
overt, as for cardiovascular disease,113 reliance on data
from supplemental studies in later life would be mislead-
ing, so that long term intake data, for individuals and/or
populations, will be needed to allow adequate adjust-
ments for such confounding. Similarly, assessment of
intakes of nutrients interacting with vitaminD (including
vitamins A, K, and C, calcium and magnesium) in future
studies, and adjustment for those intakes, would allow
better evaluation of vitamin D’s independent health
effects.119
Conclusion
Although there are occasional reports in the peer-
reviewed journal literature of U-like serum 25(OH)D
concentration–health outcome relationships, few are
consistent, or reﬂect identiﬁable underlying patho-
physiological processes, apart from allergic reactions,
probably reﬂecting the shifting of the Th1–Th2 cell
balance toward Th2, with increased production of
pro-inﬂammatory cytokines. In some people with
CVD, an adverse effect of higher 25(OH)D concentra-
tion might be possible. In other conditions a highly
plausible reason for these ﬁndings is that people who
had been vitamin D insufﬁcient over many years had
started taking vitamin D supplements too late in life
to correct disorders aggravated by poor vitamin D sta-
tus. Future observational studies, including RCTs,
should, therefore, collect data on vitamin D
supplementation, solar UVB exposure, and the intakes
of potentially confounding nutrients (e.g., calcium,
magnesium, vitamins A, K, C and E), and should use
standardized 25(OH)D assays. Furthermore, the
results of clinical trials of vitamin D supplementation,
including the 5 or 6 major trials now underway,
should be examined for evidence of increased risk at
higher 25(OH)D concentrations, although substantial
side effects are unlikely at the vitamin D3 doses that
were used in these studies (< 10,000 IU/day).
Abbreviations
25(OH)D 25-hydroxyvitamin D
CI conﬁdence interval
CVD cardiovascular disease
DEQAS Vitamin D External Quality Assessment
FFA free fatty acids
HR hazard ratio
IU international units
MACCE major adverse cardiac and cerebrovascular
events during of cardiac surgery or while
still at the hospital
MACS mortality or acute coronary syndrome
MR mortality rate
nmol/L nanomols/liter
NCC nested case–control
OR odds ratio
PC prostate cancer
RR relative risk
Th T-helper
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